(Q36402637)

English

The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 August 2017

The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy (English)

1 reference

Europe PubMed Central

14 August 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Jeffrey Ravetch

4

object named as

Jeffrey V Ravetch

1 reference

Europe PubMed Central

14 August 2017

author name string

Junji Uchida

1

1 reference

Europe PubMed Central

14 August 2017

Yasuhito Hamaguchi

2

1 reference

Europe PubMed Central

14 August 2017

Julie A Oliver

3

1 reference

Europe PubMed Central

14 August 2017

Jonathan C Poe

5

1 reference

Europe PubMed Central

14 August 2017

Karen M Haas

6

1 reference

Europe PubMed Central

14 August 2017

Thomas F Tedder

7

1 reference

Europe PubMed Central

14 August 2017

language of work or name

0 references

publication date

1 June 2004

1 reference

Europe PubMed Central

14 August 2017

Journal of Experimental Medicine

1 reference

Europe PubMed Central

14 August 2017

199

1 reference

Europe PubMed Central

14 August 2017

12

1 reference

Europe PubMed Central

14 August 2017

1659-1669

1 reference

Europe PubMed Central

14 August 2017

Mouse CD20 expression and function

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

Complement activation selectively potentiates the pathogenicity of the IgG2b and IgG3 isotypes of a high affinity anti-erythrocyte autoantibody

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

Immunotherapy of Non-Hodgkin's lymphomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

Inflammation in autoimmunity: receptors for IgG revisited

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fcgamma receptor III.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

High pathogenic potential of low-affinity autoantibodies in experimental autoimmune hemolytic anemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

Monoclonal antibody therapy of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

Essential role of LAT in T cell development

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

FcgammaRIII (CD16)-deficient mice show IgG isotype-dependent protection to experimental autoimmune hemolytic anemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

Identification of the mouse IgG3 receptor: implications for antibody effector function at the interface between innate and adaptive immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

Immunoglobulin G-mediated inflammatory responses develop normally in complement-deficient mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

FcR gamma chain deletion results in pleiotrophic effector cell defects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

CD20: a regulator of cell-cycle progression of B lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

Tissue-specific expression of the human CD19 gene in transgenic mice inhibits antigen-independent B-lymphocyte development.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

30 September 2017

Complement activation determines the therapeutic activity of rituximab in vivo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

28 June 2018

Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

28 June 2018

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

28 June 2018

Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

28 June 2018

Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

28 June 2018

Activation of mouse complement by different classes of mouse antibody

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

28 June 2018

FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

21 September 2018

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

21 September 2018

Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

21 September 2018

Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

21 September 2018

Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

21 September 2018

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

21 September 2018

Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

21 September 2018

A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

21 September 2018

Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.

1 reference

https://api.crossref.org/works/10.1084%2FJEM.20040119

21 January 2018

Repeat-induced gene silencing in mammals.

1 reference

https://api.crossref.org/works/10.1084%2FJEM.20040119

21 January 2018

Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents

1 reference

https://api.crossref.org/works/10.1084%2FJEM.20040119

21 January 2018

Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2212805

5 December 2018

Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/15210744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

1 reference

https://pubmed.ncbi.nlm.nih.gov/15210744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies

1 reference

https://pubmed.ncbi.nlm.nih.gov/15210744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor-primed effector cells and Hu1D10--a humanized human leucocyte antigen DR antibody

1 reference

https://pubmed.ncbi.nlm.nih.gov/15210744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Divergent roles for Fc receptors and complement in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/15210744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15210744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils

1 reference

https://pubmed.ncbi.nlm.nih.gov/15210744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cellular requirements for the monoclonal antibody-mediated eradication of an established solid tumor

1 reference

https://pubmed.ncbi.nlm.nih.gov/15210744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Complement activation plays a key role in the side-effects of rituximab treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/15210744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of antibody isotype on passive serotherapy of lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15210744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59

1 reference

https://pubmed.ncbi.nlm.nih.gov/15210744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants

1 reference

https://pubmed.ncbi.nlm.nih.gov/15210744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy with monoclonal antibodies. II. The contribution of Fc gamma receptor binding and the influence of C(H)1 and C(H)3 domains on in vivo effector function

1 reference

https://pubmed.ncbi.nlm.nih.gov/15210744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15210744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of colony stimulating factor-1 in the establishment and regulation of tissue macrophages during postnatal development of the mouse

1 reference

https://pubmed.ncbi.nlm.nih.gov/15210744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity

1 reference

https://pubmed.ncbi.nlm.nih.gov/15210744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-B1 monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15210744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/15210744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activation of mouse complement by monoclonal mouse antibodies

1 reference

https://pubmed.ncbi.nlm.nih.gov/15210744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies

1 reference

https://pubmed.ncbi.nlm.nih.gov/15210744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor

1 reference

https://pubmed.ncbi.nlm.nih.gov/15210744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical status and optimal use of rituximab for B-cell lymphomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/15210744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1084/JEM.20040119

1 reference

Europe PubMed Central

14 August 2017

1 reference

Europe PubMed Central

14 August 2017

1 reference

Europe PubMed Central

14 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36402637&oldid=1518919879"